Propanc Biopharma, Inc. (PPCB)
USD 5.5
(-25.98%)
USD 5.5
(-25.98%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -34.15 Thousand USD | -18.41% |
| 2023 | -28.84 Thousand USD | -1.67% |
| 2022 | -28.36 Thousand USD | -0.9% |
| 2021 | -28.11 Thousand USD | 14.32% |
| 2020 | -32.8 Thousand USD | -16.92% |
| 2019 | -28.06 Thousand USD | 8.06% |
| 2018 | -30.52 Thousand USD | -1309.1% |
| 2017 | -2166.00 USD | -146.98% |
| 2016 | -877.00 USD | 76.42% |
| 2015 | -3719.00 USD | 66.24% |
| 2014 | -11.01 Thousand USD | 14.46% |
| 2013 | -12.87 Thousand USD | 0.0% |
| 2012 | -12.87 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -5857.00 USD | 18.07% |
| 2024 Q3 | -4773.00 USD | 18.51% |
| 2024 Q4 | -5764.00 USD | -20.76% |
| 2024 Q1 | -7149.00 USD | -8.37% |
| 2023 FY | -28.84 Thousand USD | -1.67% |
| 2023 Q1 | -6373.00 USD | -52.9% |
| 2023 Q4 | -6597.00 USD | 21.14% |
| 2023 Q3 | -8365.00 USD | -11.44% |
| 2023 Q2 | -7506.00 USD | -17.78% |
| 2022 Q3 | -8157.00 USD | -24.53% |
| 2022 FY | -28.36 Thousand USD | -0.9% |
| 2022 Q4 | -4168.00 USD | 48.9% |
| 2022 Q2 | -6550.00 USD | 15.33% |
| 2022 Q1 | -7736.00 USD | -1370.72% |
| 2021 FY | -28.11 Thousand USD | 14.32% |
| 2021 Q1 | - USD | 100.0% |
| 2021 Q3 | -9231.00 USD | -19.11% |
| 2021 Q4 | -526.00 USD | 94.3% |
| 2021 Q2 | -7750.00 USD | 0.0% |
| 2020 Q3 | -7591.00 USD | 0.01% |
| 2020 Q4 | -6994.00 USD | 7.86% |
| 2020 FY | -32.8 Thousand USD | -16.92% |
| 2020 Q1 | -10.63 Thousand USD | -69.11% |
| 2020 Q2 | -7592.00 USD | 28.59% |
| 2019 Q2 | -6449.00 USD | 20.17% |
| 2019 Q3 | -7248.00 USD | -12.39% |
| 2019 Q4 | -6287.00 USD | 13.26% |
| 2019 FY | -28.06 Thousand USD | 8.06% |
| 2019 Q1 | -8078.00 USD | -19.02% |
| 2018 Q3 | -8005.00 USD | -16.03% |
| 2018 Q2 | -6899.00 USD | 21.87% |
| 2018 Q1 | -8830.00 USD | -139.71% |
| 2018 Q4 | -6787.00 USD | 15.22% |
| 2018 FY | -30.52 Thousand USD | -1309.1% |
| 2017 FY | -2166.00 USD | -146.98% |
| 2017 Q4 | 22.23 Thousand USD | 390.72% |
| 2017 Q3 | -7649.00 USD | -27.67% |
| 2017 Q2 | -5991.00 USD | 30.31% |
| 2017 Q1 | -8597.00 USD | -157.08% |
| 2016 FY | -877.00 USD | 76.42% |
| 2016 Q1 | -4938.00 USD | -223.73% |
| 2016 Q2 | -4889.00 USD | 0.99% |
| 2016 Q3 | -5235.00 USD | -7.08% |
| 2016 Q4 | 15.06 Thousand USD | 387.72% |
| 2015 Q1 | -2777.00 USD | -33.19% |
| 2015 Q4 | 3991.00 USD | 268.68% |
| 2015 Q3 | -2366.00 USD | 7.83% |
| 2015 Q2 | -2567.00 USD | 7.56% |
| 2015 FY | -3719.00 USD | 66.24% |
| 2014 Q3 | -3403.00 USD | -22.28% |
| 2014 FY | -11.01 Thousand USD | 14.46% |
| 2014 Q1 | -2745.00 USD | 0.0% |
| 2014 Q2 | -2783.00 USD | -1.38% |
| 2014 Q4 | -2085.00 USD | 38.73% |
| 2013 Q3 | -3403.00 USD | -2.01% |
| 2013 Q4 | - USD | 100.0% |
| 2013 FY | -12.87 Thousand USD | 0.0% |
| 2013 Q1 | -12.87 Thousand USD | 0.0% |
| 2013 Q2 | -3336.00 USD | 74.1% |
| 2012 Q2 | -3210.00 USD | 0.0% |
| 2012 Q3 | -4367.00 USD | -36.04% |
| 2012 Q1 | - USD | 0.0% |
| 2012 FY | -12.87 Thousand USD | 0.0% |
| 2012 Q4 | - USD | 100.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -1300.164% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 100.292% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 89.312% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.029% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.868% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 29.236% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 72.515% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.228% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 1200.903% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 100.349% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 151.957% |
| Mesoblast Limited | -35.16 Million USD | 99.903% |
| Marizyme, Inc. | 457.7 Thousand USD | 107.461% |
| Genus plc | 178.7 Million USD | 100.019% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.016% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 154.881% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 108.326% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -210.455% |
| ContraFect Corporation | -154 Thousand USD | 77.825% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 31.7% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 144.489% |
| IMV Inc. | -962.29 Thousand USD | 96.451% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 91.187% |
| MultiCell Technologies, Inc. | 49.32 USD | 69341.687% |
| ONE Bio Corp. | 20.12 Million USD | 100.17% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.085% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 169.836% |
| Q BioMed Inc. | -8988.00 USD | -279.951% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.121% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -121.408% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.077% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 97.009% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 148.786% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -589.62% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 124.306% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 64.98% |
| GB Sciences, Inc. | -624.00 USD | -5372.756% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 60.304% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -16318.269% |
| Enzolytics Inc. | 30.7 Thousand USD | 211.209% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 107.079% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.003% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 93.363% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 105.531% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.008% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -285.614% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 59.272% |
| Kadimastem Ltd | -630.13 Thousand USD | 94.581% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 103.457% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 100.355% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.221% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -188.551% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 119.342% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 119.342% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 102.516% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -17.759% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 107.588% |
| SYBLEU INC | 11.69 Thousand USD | 391.98% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 100.741% |
| Bioxytran, Inc. | -8285.00 USD | -312.191% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 90.845% |
| Neutra Corp. | 14.33 Thousand USD | 338.228% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 58.354% |
| PureTech Health plc | -1.6 Million USD | 97.87% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 96.589% |
| IXICO plc | 3.27 Million USD | 101.044% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 95.079% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 98.093% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | 289.722% |